Achaogen to Present New Data on ACHN-490 at the 50th Annual ICAAC Meeting

Presentations Highlight Data from Phase 1 Study with ACHN-490 and In Vitro Activity of ACHN-490 Against Resistant Bacterial Pathogens and in Combination with Existing Antibiotics

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Achaogen, a biopharmaceutical company discovering and developing antibiotics to treat life-threatening, multi-drug resistant (MDR) bacterial infections, today announced key upcoming data presentations involving its lead antibiotic candidate ACHN-490. The data are being presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Boston from September 12th through September 15th, 2010.

  • Monday, September 13th from 11:15 am to 1:15 pm: Poster A1-658/7, entitled “Pharmacokinetics (PK) and Safety of ACHN-490 Injection Administered Intravenously for Five Days in Healthy Human Subjects.”
  • Tuesday, September 14th from 11:15 am to 1:15 pm: Poster E-1563/226, entitled “Activity of ACHN-490 Against Isolates of Methicillin-resistant Staphylococcus aureus (MRSA) from Patients in U.S. Hospitals.”
  • Wednesday, September 15th from 9:00 am to 11:00 am: Poster E-2059/74, entitled “Activity of ACHN-490, a Neoglycoside, against E. coli (EC) and K. pneumoniae (KP) isolates from New York City (NYC).”
  • Wednesday, September 15th from 9:00 am to 11:00 am: Poster E-2048/63, entitled “Activity of ACHN-490 +/- Cefepime, Doripenem, Imipenem, or Piperacillin/Tazoactam Against 10 P. aeruginosa by Synergy Time-Kill.”

In addition to the poster presentations, on Monday, September 15th from 9:00 am to 9:30 am, George H. Miller, Ph.D., research fellow at Achaogen, will be presenting “Aminoglycosides: Past, Present and Future” as part of the Symposium: “Antibiotic Drug Discovery: How Far Have We Come in 50 Years?”

Following the meeting, full versions of the posters will be available on the Achaogen website at www.achaogen.com.

About ACHN-490

Achaogen’s most advanced compound, ACHN-490, has been chemically engineered to retain activity against bacteria resistant to carbapenems, cephalosporins, fluoroquinolones, tetracyclines, and legacy aminoglycosides. The compound has demonstrated bactericidal activity in vitro and efficacy in preclinical studies against systemic infections caused by MDR Gram-negative bacteria (e.g., K. pneumoniae, E. coli, and P. aeruginosa) and MRSA. ACHN-490 Injection is currently being investigated in a randomized, double-blind, comparator-controlled Phase 2 clinical study for the treatment of complicated urinary tract infection (cUTI), the most commonly treated hospital infections in the U.S., and acute pyelonephritis.

About Achaogen

Achaogen is a biopharmaceutical company focused on the discovery and development of antibiotics to treat multi-drug resistant bacterial infections. Resistance to available antibacterial therapies continues to rise at an alarming rate, and Achaogen is applying its anticipatory science to meet this evolving need, developing drugs today intended to combat tomorrow’s resistant pathogens. Achaogen has established specialized capabilities that have enabled the company to pursue multiple discovery and development programs, and has funded its growth with an innovative blend of private investments and non-dilutive funding from partnerships with the NIH, BARDA, the United States Department of Defense, and others. For more information, please visit the company’s website at www.achaogen.com.



CONTACT:

Pure Communications
Ashlea Kosikowski, 910-547-7093

KEYWORDS:   United States  North America  California  Massachusetts  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Infectious Diseases  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.